Jonathan Swank, MD
Internal Medicine · Abingdon, VANPI 1750459228
Payments from drug & device makers
Across 318 payments — averaging $15.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$776
- AstraZeneca$544
- Johnson & Johnson$415
- Pfizer$366
- Lilly USA, LLC$345
- AbbVie$312
- plus $2K from 28 others
What the payments were for
- Food & beverage$4,888100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 58 | $776 |
| AstraZeneca | 35 | $544 |
| Johnson & Johnson | 29 | $415 |
| Pfizer | 23 | $366 |
| Lilly USA, LLC | 22 | $345 |
| AbbVie(2 entities) | 20 | $312 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $276 |
| Amgen | 13 | $209 |
| GSK | 14 | $204 |
| E.r. Squibb & Sons, L.L.C. | 9 | $159 |
| Novartis | 9 | $156 |
| Amarin Pharma, Inc. | 9 | $141 |
| Exact Sciences | 6 | $132 |
| Merck | 9 | $123 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $118 |
| Arbor Pharmaceuticals, Inc. | 7 | $99 |
| Esperion Therapeutics, Inc. | 5 | $93 |
| Abbott | 3 | $65 |
| Boehringer Ingelheim | 3 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Eisai Inc. | 2 | $29 |
| Tactile Systems Technology Inc | 1 | $27 |
| Bayer | 1 | $26 |
| CSL Behring | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Medtronic | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$4,902 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 243 | $258,592 |
| EliquisApixaban | 297 | $247,732 |
| TrulicityDulaglutide | 143 | $145,599 |
| JardianceEmpagliflozin | 77 | $85,060 |
| MounjaroTirzepatide | 57 | $66,598 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 86 | $66,503 |
| XareltoRivaroxaban | 50 | $51,739 |
| JanuviaSitagliptin Phosphate | 56 | $44,201 |
| XifaxanRifaximin | 12 | $39,412 |
| LinzessLinaclotide | 40 | $28,680 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $20,548 |
| FarxigaDapagliflozin Propanediol | 35 | $20,121 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $19,000 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 113 | $14,353 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $13,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $776 | $258,592243 claims |
| PfizerEliquis | $366 | $247,732297 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $345 | $212,198200 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $204 | $96,487139 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $49 | $91,38789 claims |
| MerckJanuvia, Janumet | $123 | $57,41167 claims |
| Johnson & JohnsonXarelto | $415 | $51,73950 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $276 | $39,41212 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $544 | $35,10773 claims |
| AbbVieLinzess, Synthroid | $312 | $32,22390 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $99 | $8,37519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Abingdon
- Andrew RhinehartAbingdon$112K
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.